



CHEMICAL MANUFACTURERS ASSOCIATION

January 3, 1995

Dear Vinyl Chloride Health Committee Members:

The agenda for the January 30, 1995 meeting is enclosed. As mentioned in my December 9, 1994 letter, Drs. Ken Mundt and Carlo Tamburo will attend the meeting. Discussion with Dr. Mundt will enable him to collect new data for the epidemiology update more efficiently. Discussion with Dr. Tamburo will enable the Committee to decide on a course of action with respect to the proposed brain cancer case control study.

The October 6 and 7, 1994 Records of Meeting and subsequent Records of Conference Call are being mailed to you separately. Information on agenda items 5.0, 6.0, and 7.0 is enclosed. I will follow-up with Dr. Holtzer of Cal-EPA on vinyl chloride risk assessment near a hazardous waste landfill. Please discuss Dr. James Swenberg's proposal with your toxicologists prior to the meeting. I will request a more detailed proposal from Dr. Swenberg if the project merits further consideration. I will contact Dr. James Cogliano of EPA to learn the process for modifying the Heast Table. The Heast Table predicts a much higher vinyl chloride unit risk than estimated by Richard Reitz based on the pharmacokinetic data.

I am looking forward to seeing you on January 30 and I wish you a very happy new year!

Sincerely,

Hasmukh C. Shah, Ph.D.
Manager, Vinyl Chloride Panel

Enclosures

BFG 00122

CHEMICAL MANUFACTURERS ASSOCIATION

Vinyl Chloride Health Committee

Tentative Agenda

Date: January 30, 1995
Time: 10:30 a.m. - 3:30 p.m. EST
Place: CMA Offices
2501 M Street, NW
Washington, D.C.

- 1.0 Approval of October 6 and 7, 1994 Records of Meeting
- 2.0 Discussion of Vinyl Chloride Epidemiology Study Update with Ken Mundt *See handwritten notes re: 10/6/94*
- 3.0 Discussion of University of Louisville's Proposal for a Brain Cancer Case Control Study with Carlo Tamburo *Follow up conf call on Monday 2/6/95 @ 2 PM (to re-evaluate proposal).*
- 4.0 Status of ATSDR and EPA Responses to the Committee's November 28 Letters for a Negotiated Voluntary Program and Discussion of a Course of Action with Caffey Norman *Random to chair. Done from Agency. Testing protocol. { Can expect response to ATSDR should be within next 30 days. }*
- 5.0 Status of Cal-EPA Risk Assessment of Vinyl Chloride Near a Hazardous Waste Landfill *See 1/27/95 letter from Cal EPA (Heather Kelly) to Has Shah. Random to discuss w/ Kelly.*
- 6.0 Discussion of Richard Reitz's Manuscript and the Committee's Course of Action with Respect to Modification of the Heast Table *Procedure to be clarified & communicated.*
- 7.0 Discussion of James Swenberg's Research Proposal
- 8.0 Discussion of International Workshop on Vinyl Chloride
- 9.0 Distribution of Financial Statement
- 10.0 Set Date for Next Meeting or Conference Call

Has Shah

Hasmukh C. Shah, Ph.D.
Manager, Vinyl Chloride Panel

Subject to Approval



THE UNIVERSITY OF NORTH CAROLINA
AT
CHAPEL HILL

The School of Public Health
Department of
Environmental Sciences and Engineering

The University of North Carolina at Chapel Hill
CB# 7400, Rosenau Hall
Chapel Hill, N.C. 27599-7400

October 19, 1994

Dr. Hasrmukh C. Shah
Manager, Vinyl Chloride Panel
Chemical Manufacturers Association
2501 M Street, NW
Washington, D.C. 20037

Dear Dr. Shah:

I enjoyed seeing you at the CIIT Open House last week. This letter is a follow up to our conversation regarding the discussions that the Vinyl Chloride Panel held following our visit to the EPA. I would be interested in working with you on some of the issues that are still of concern such as determining the $T_{1/2}$ of the ethenoguanine DNA adduct (EG), and quantitating the amount of the methyl purine DNA glycosylase (MPG) and P450 2E1 in tissues of humans of different ages.

We discussed the approach that I would use to determine the $T_{1/2}$ of EG. This would require the synthesis of [$^{13}\text{C}_2$]-vinyl chloride. I would then expose groups of 3-4 rats using the closed chamber technique to the stable isotope and sacrifice them at different times (0, 4, 12, and 24 hours) after a 6 hour exposure to ~1000 ppm VC. This would be repeated several times to determine the average $T_{1/2}$ of EG using our GC/ high resolution MS methodology. Dr. Johannes Filser will visit me next week and I plan on discussing the details of the animal exposure with him, as he is an expert in the closed chamber technique.

We are just setting up a quantitative polymerase chain reaction (PCR) method for measuring the expression of the MPG DNA repair protein. We plan to evaluate age differences in rats and mice under our Superfund Basic Research Program proposal, providing it gets funded. What I hadn't considered until I met with the VC Panel was doing this in human tissues of different ages. This may require slight adjustments in methodology and the synthesis of different primers. I believe that I can obtain human tissues from various tissue banks such as Vanderbilt University and the University of

TO :
FROM :

PHONE NO. : 0012018986633

OCT. 12. 1994 11:48PM P 1



ASSOCIATION OF PLASTICS
MANUFACTURERS IN EUROPE

Brussels, 12 October 1994

To the attention of Mrs. Meredith Scheck
The Vinyl Institute
Fax: 00-1-201-890-7029
838-6633

This note to let you know that I have been contacted recently by Mr. R. Holtzer M.D. from California - Environmental Protection Agency, Hazardous Waste Toxicology Section, requesting information about the cases of ASL linked to occupational exposure to VCM. The Agency is conducting a "Health risk assessment of exposure to Vinyl Chloride in a residential community immediately adjacent to and downwind from a closed hazardous waste landfill".

I sent some extracts of the ASL Register, and specified that all the reported ASL cases occurred after a continuous and very high exposure to VCM and that, so far, there has not been any ASL cases reported by workers first exposed after the mid-seventies, which is the time when exposure to VCM was drastically reduced in Vinyls plants.

Yours sincerely

A handwritten signature in black ink, appearing to read 'F. Drion', with a long horizontal line extending from the end of the name.

F. Drion M.D.
Medical Working Group of A.P.M.E.

BFG 00127 &

** TOTAL PAGE.02 **